Trial reportBMC pediatrics2025
Influence of antenatal steroids on the effect of early inhaled postnatal corticosteroids: a post-hoc analysis of the NEuroSIS trial.
Trial report in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew data are available on the interplay of antenatal and early inhaled postnatal corticosteroids. The NEuroSIS trial randomized extremely preterm infants to receive either early inhaled budesonide or placebo and analyzed the effect of study medication on bronchopulmonary dysplasia or death, as well as the effect on neurodevelopmental outcome at 18-22 months corrected age. Application of antenatal steroids may have had an influence on these outcomes.
objectiveTo analyze if antenatal corticosteroids (ANS) influenced the short- (BPD and death before 36 weeks PMA) and long-term (disability at 18-22 months corrected age or death before time of assessment) effects of early inhaled postnatal budesonide in NEuroSIS study participants.
methodsPost-hoc analysis of the intention-to-treat population of the NEuroSIS study. Generalized logits models were used to (1) predict risk of BPD, death before 36 weeks PMA and survival without BPD with application of ANS, NEuroSIS study treatment and gestational age as independent variables and (2) predict the risk of disability at 18-22 months corrected age, death before time of neurodevelopmental assessment and survival without disability, with ANS and gestational age as independent variables.
resultsApplication of ANS, added as an independent variable, did not change the effect of study medication on developing BPD (OR 0.79, 95% CI 0.67-0.93) and there was no association with the risk of death (OR 1.03, 95% CI 0.84-1.27) at 36 weeks PMA. ANS added as an independent variable showed an association with a reduced risk of death before time of completion of neurodevelopmental assessment (OR 0.60, 95% CI 0.44-0.81) and was associated with a reduced risk of disability at 18-22 months corrected age(OR 0.63, 95% CI 0.49-0.81).
conclusionANS did not alter the reduction of BPD risk by study medication and there was no association with increased mortality in NEuroSIS study participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.